Akron Children's Logo
Skip to main content
Close Tools Menu Icon

Operator:

330-543-1000

Questions or Referrals:
ASK CHILDREN‘S

Close Phone Menu Icon
Akron Children's > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies

Safety and Efficacy of Fesoterodine in Children with Bladder Overactivity

Full IRB Study Title:
A 24-week Randomized, Open-label, Study To Evaluate The Safety And Efficacy Of Fesoterodine In Subjects Aged 6 To 17 Years With Symptoms Of Detrusor Over activity Associated With A Neurological Condition (Neurogenic Detrusor Over activity)

IRB Study ID: 120613

Fesoterodine is a drug approved in Europe and USA to treat an overactive bladder condition known in adults but due to lack of research it is not yet FDA approved for children. This bladder condition has been associated with damage to the nervous system and is known as Neurogenic detrusor over activity (NDO).

The purpose of this trial is to study the effects of the Fesoterodine medicine provided to children diagnosed with NDO. We will also compare the effects of Fesoterodine with Oxybutynin, a widely approved medicine commonly used to treat NDO in children.

For more information visit: https://clinicaltrials.gov/ct2/show/NCT01557244?term=Fesoterodine&rank=1

Study Sponsor:

Pfizer, Inc.

Who May Qualify:

Children between 6-17 years of age diagnosed with neurogenic detrusor overactivity (NDO).

Lead Investigator

Daniel McMahon

Daniel McMahon, MD

Director, Pediatric Urology; Pediatric Urologist


Pediatric UrologyKidney Stone Clinic

More about this provider

Back to top of page

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.